The money will be used to fuel the growth and adoption of HTG’s multi-plex gene expression testing platform for validation and clinical applications across different therapeutic areas.
Read MoreNet proceeds will go to support the company’s research and development activities, including expenses involved in gaining US regulartory approval of Surfaxin.
Read MoreThe study will evaluate Nexavar in combination with capecitabine in patients with locally advanced or metastatic HER-2 negative breast cancer.
Read MoreSunesis Pharmaceuticals’ vosaroxin would be used in combination with cytarabine to treat acute myeloid leukemia.
Read MoreSmoothened inhibition with IPI-926 represents a potentially new approach to addressing difficult-to-treat cancer.
Read More